AR011726A1 - Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento - Google Patents

Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento

Info

Publication number
AR011726A1
AR011726A1 ARP980102089A ARP980102089A AR011726A1 AR 011726 A1 AR011726 A1 AR 011726A1 AR P980102089 A ARP980102089 A AR P980102089A AR P980102089 A ARP980102089 A AR P980102089A AR 011726 A1 AR011726 A1 AR 011726A1
Authority
AR
Argentina
Prior art keywords
cox
acids
procedure
activity
prevention
Prior art date
Application number
ARP980102089A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR011726A1 publication Critical patent/AR011726A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Tratamiento o prevencion de procesos y enfermedades inflamatorias en perros asociadas con la actividad de la ciclo-oxigenasa-2 (COX-2) inducible, mientrasque al mismo tiempo se reducen o eliminan los efectos secundarios indeseables asociados conla inhibicion simultánea de la actividad de la ciclo-oxigenasa-1(COX-1) constitutiva, mediante la inhibicion selectiva de la actividad de COX-2 con respecto a la actividad de la COX-1, donde la relacionde selectividadde COX-2:COX-1 es al menos3: 1 basándose en los niveles de inhibicion ex vivo medidos en sangre entera; el inhibidor es un miembro seleccionado entre elgrupo de compuestos anti-inflamatorios que consta esencialmente de derivados del ácido salicílico; derivados dep-aminofen ol; ácidos indol e idenoacéticos;ácidos heteroaril acéticos; ácidos arilpropionicos; ácidos antranílicos; ácidos enolicos; y alcanonas; el inhibidor, en particular, está compuesto por elenantiomero (-) (S) del ácido6-cloro-alfa-metil-9H-carbazol-2- acético.
ARP980102089A 1997-05-05 1998-05-05 Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento AR011726A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4563597P 1997-05-05 1997-05-05

Publications (1)

Publication Number Publication Date
AR011726A1 true AR011726A1 (es) 2000-08-30

Family

ID=21939053

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980102089A AR011726A1 (es) 1997-05-05 1998-05-05 Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento
ARP030101251A AR039628A2 (es) 1997-05-05 2003-04-09 Formulacion masticable de carprofeno, implante y composicion terapeutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP030101251A AR039628A2 (es) 1997-05-05 2003-04-09 Formulacion masticable de carprofeno, implante y composicion terapeutica

Country Status (32)

Country Link
EP (1) EP0988034A1 (es)
JP (1) JP2000513020A (es)
KR (2) KR20040004406A (es)
CN (1) CN1255059A (es)
AP (1) AP9801234A0 (es)
AR (2) AR011726A1 (es)
AU (1) AU6932198A (es)
BG (1) BG103852A (es)
BR (1) BR9808720A (es)
CA (1) CA2288759A1 (es)
DZ (1) DZ2479A1 (es)
EA (1) EA003696B1 (es)
GT (1) GT199800063A (es)
HR (1) HRP980244A2 (es)
HU (1) HUP0001286A3 (es)
ID (1) ID21311A (es)
IL (1) IL132570A0 (es)
IS (1) IS5220A (es)
MA (1) MA26491A1 (es)
NO (1) NO995389L (es)
NZ (1) NZ500183A (es)
OA (1) OA11213A (es)
PA (1) PA8450601A1 (es)
PE (1) PE72599A1 (es)
PL (1) PL337003A1 (es)
SK (1) SK148199A3 (es)
TN (1) TNSN98059A1 (es)
TW (1) TW590773B (es)
UY (1) UY24989A1 (es)
WO (1) WO1998050033A1 (es)
YU (1) YU55899A (es)
ZA (1) ZA983722B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245797B1 (en) 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
AU2003204888B2 (en) * 1998-05-22 2005-07-28 Pfizer Products Inc. Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives
US6506785B2 (en) 1998-05-22 2003-01-14 Pfizer, Inc. Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
CA2347365A1 (en) * 1998-10-23 2000-05-04 Merck Frosst Canada & Co. Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
WO2000053149A2 (en) * 1999-03-10 2000-09-14 G.D. Searle & Co. Method and composition for administering a cyclooxygenase-2 inhibitor
WO2001034204A1 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
CA2407469A1 (en) * 2000-05-15 2001-11-22 Merck Frosst Canada & Co. Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
US6924303B2 (en) 2000-06-13 2005-08-02 Wyeth Analgesic and anti-inflammatory compositions containing COX-2 inhibitors
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
ATE421595T1 (de) 2000-08-07 2009-02-15 Univ Vanderbilt Zusammensetzungen und verfahren zum nachweis und zur quantifizierung von cox-2-aktivität und 2- arachidonylglycerin-metaboliten
US20040209959A1 (en) * 2001-07-16 2004-10-21 Edward Hogestatt Congeners of acetaminophen and related compounds as substrates for fatty acid conjugation and their use in treatment of pain, fever and inflammation
DE602004002832T2 (de) 2003-05-07 2007-06-06 Osteologix A/S Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
CN1829510A (zh) * 2003-07-31 2006-09-06 法马西亚和厄普乔恩公司 抗炎剂的可分散性制剂
CA2608010A1 (en) * 2005-05-20 2006-11-23 Pfizer Limited Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands
US9114071B2 (en) 2007-04-04 2015-08-25 Sigmoid Pharma Limited Oral pharmaceutical composition
US8951570B2 (en) 2007-04-26 2015-02-10 Sigmoid Pharma Limited Manufacture of multiple minicapsules
WO2010133609A2 (en) 2009-05-18 2010-11-25 Sigmoid Pharma Limited Composition comprising oil drops
GB2485327A (en) 2009-08-12 2012-05-09 Sigmoid Pharma Ltd Immunomodulatory compositions comprising a polymer matrix and an oil phase
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
PL3113774T3 (pl) 2014-03-06 2022-06-13 Elanco Animal Health Incorporated Kompozycje grapiprantu i sposoby ich zastosowania
AU2015341695B2 (en) 2014-11-07 2021-07-08 Sublimity Therapeutics Limited Compositions comprising cyclosporin
CA2972996A1 (en) * 2015-01-09 2016-07-14 Jaguar Animal Health Methods of treating diarrhea in companion animals
EP4125874A4 (en) * 2020-03-25 2024-05-01 SRI International LIPOXYGENASE INHIBITORS
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
KR102404883B1 (ko) 2020-11-30 2022-06-07 (주)이노보테라퓨틱스 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896145A (en) * 1972-07-24 1975-07-22 Hoffmann La Roche Carbazoles
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions

Also Published As

Publication number Publication date
HUP0001286A3 (en) 2000-12-28
JP2000513020A (ja) 2000-10-03
TNSN98059A1 (fr) 2005-03-15
SK148199A3 (en) 2001-09-11
ID21311A (id) 1999-05-20
CN1255059A (zh) 2000-05-31
NO995389D0 (no) 1999-11-04
BG103852A (en) 2000-06-30
KR20010012300A (ko) 2001-02-15
EA003696B1 (ru) 2003-08-28
EP0988034A1 (en) 2000-03-29
CA2288759A1 (en) 1998-11-12
AU6932198A (en) 1998-11-27
WO1998050033A1 (en) 1998-11-12
NZ500183A (en) 2002-04-26
IS5220A (is) 1999-10-19
HRP980244A2 (en) 1999-02-28
BR9808720A (pt) 2000-07-11
GT199800063A (es) 1999-10-26
PA8450601A1 (es) 2000-05-24
ZA983722B (en) 1999-11-04
DZ2479A1 (fr) 2003-02-01
NO995389L (no) 2000-01-04
TW590773B (en) 2004-06-11
EA199900895A1 (ru) 2000-06-26
KR20040004406A (ko) 2004-01-13
AR039628A2 (es) 2005-03-02
IL132570A0 (en) 2001-03-19
AP9801234A0 (en) 1999-11-04
MA26491A1 (fr) 2004-12-20
HUP0001286A2 (hu) 2000-11-28
PL337003A1 (en) 2000-07-31
PE72599A1 (es) 1999-08-12
YU55899A (sh) 2003-08-29
OA11213A (en) 2003-07-14
UY24989A1 (es) 2001-10-25

Similar Documents

Publication Publication Date Title
AR011726A1 (es) Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento
TR200003583T2 (tr) Yeni 3-aril propiyonik asit türevleri ve benzerleri.
FR2395263A1 (fr) Derives d'acides thiadiazole-1, 2, 3 carboxyliques-5 utilisables comme matieres actives de produits herbicides
ES2159851T3 (es) Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa.
PT1039895E (pt) Utilizacao de acidos 3-benzoilfenilaceticos respectivos esteres ou amidas para o tratamento do glaucoma glc1a
RU95112575A (ru) Соль арилпропионовой кислоты, способ ее получения и фармацевтическая композиция
AR003938A1 (es) Compuestos triciclicos de urea utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proteoliticas, composicionfarmaceutica, y el uso de los mismos para la preparacion de medicamentos.
ES2120070T3 (es) Esteres nitricos dotados de una actividad anti-inflamatoria y/o analgesica y su procedimiento de preparacion.
DE69932414D1 (de) Indole-3-propionsäure, ihre salze und ester als arzneimittel
NO863935L (no) Fremgangsmaate for fremstilling av terapeutiske preparater inneholdende 2-(2-fluor-4-bifenylyl)propionsyre.
ATE50255T1 (de) Substituierte 9-fluor-3-methyl-7-oxo-2,3-dihydro7h-pyrido(1,2,3-de>(1,4>benzoxazin-6-carbonsaeur ; substituierte 5-amino-6-fluor-1,4-dihydro-4-oxochinolin-3-carbons|ure; substituierte 5-amino-6fluor-1,4-dihydro-4-oxo-1,8-naphthyridin-3- carbonsaeure; ihre derivate; diese enthaltende pharmazeutische zubereitungen und verfahren
TR200200263T2 (tr) Yeni seçiçi retinoid agonistleri
Ventura-Martínez et al. Peripheral involvement of the nitric oxide–cGMP pathway in the indomethacin-induced antinociception in rat
ES2145021T3 (es) Derivados de 1-bifenil-piridona, su preparacion y su uso como antagonistas de la angiotensina ii.
Brune Prostaglandins and the mode of action of antipyretic analgesic drugs
PT880520E (pt) Derivados da benzo¬c|quinolizina sua preparacao e uso como inibidores da 5-alfa-reductase
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
DK0853476T3 (da) Nimesulidholdigt farmaceutisk præparat til topisk anvendelse
CO5021216A1 (es) Carprofeno selectivo para cox-2, para el tratamiento del dolor e inflamacion en perros
US4483854A (en) Systemic treatment of psoriasis using certain salicylates
GT199900171A (es) Concentrado oral de sertralina.
FI893677A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 6-fluori-3,5-dihydroksikarboksyylihappojen ja niiden johdannaisten valmistamiseksi
ES2184150T3 (es) Uso de derivados de los acidos 7-(1-aminometil-2-oxa-7-aza-biciclo(3.3.0)oct-7il)-quinoloncarboxilico y -naftiridoncarboxilico para el tratamiento de infecciones causadas por helicobacter pylori y de las afecciones gastroduodenales asociadas con ellas.
ATE297926T1 (de) Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
Calhoun et al. Interaction studies of tilomisole, aspirin, and naproxen in acute and chronic inflammation with assessment of gastrointestinal irritancy in the rat

Legal Events

Date Code Title Description
FB Suspension of granting procedure